A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: The Bosentan Patient Registry
收藏数据链接：
官方服务：
资源简介：
A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: The Bosentan Patient Registry
创建时间：
2026-03-27
